Clinical application of radiolabeled FAPIs in non-malignant lesions / 中华核医学与分子影像杂志
Chinese Journal of Nuclear Medicine and Molecular Imaging
; (6): 51-55, 2024.
Article
Dans Zh
| WPRIM
| ID: wpr-1027915
Responsable en Bibliothèque :
WPRO
ABSTRACT
Fibroblast activation protein inhibitor (FAPI) has been the focus of nuclear medicine since its introduction. With the in-depth study of FAPI tracer, its clinical application in various non-malignant diseases has also been gradually reported. Many studies have confirmed its uptake in a variety of non-malignant diseases, which indicate that FAPI tracers have good application prospects. This article reviews the latest research status and clinical application of radiolabeled FAPIs in cardiovascular diseases, rheumatic immune diseases, immunoglobulin (Ig)G4-related diseases, renal fibrosis and other non-malignant diseases at home and abroad.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Chinese Journal of Nuclear Medicine and Molecular Imaging
Année:
2024
Type:
Article